

CURRICULUM VITAE (Short Version)

Dr. Fabio Efficace

EDUCATION

- 2004, PhD University of Amsterdam, The Netherlands
Faculty of Medicine, Academic Medical Center (AMC)
Dissertation title: *The Value of Quality of Life Assessment In Cancer Clinical Trials.*
- 1998, MSc University of Rome "Sapienza", Rome, Italy
Faculty of Psychology, Department of Clinical Psychology.

POSITIONS, POSTGRADUATE TRAINING AND HONORS

Employment

2016-Present
Professor (Adjunct)
Northwestern University, Feinberg School of Medicine
Department of Medical Social Sciences
Chicago, Illinois (USA)

2007-Present
Head, Health Outcomes Research Unit
Italian Group for Adult Hematologic Disease (GIMEMA)
GIMEMA Data Center, Rome, Italy.

2006-2007
Head, Quality of Life Unit
Mediterranean Institute of Haematology (IME), Rome, Italy

2004–2006
Patient Reported Outcome Specialist
European Organization for Research and Treatment of Cancer (EORTC).
EORTC Data Center. Quality of Life Unit. Brussels, Belgium.

2001–2004
Research Fellow
European Organization for Research and Treatment of Cancer (EORTC).
EORTC Data Center. Quality of Life Unit. Brussels, Belgium.

Selected-postgraduate training courses

Quality of life Assessment in Cancer Clinical Trials; Clinical Trial Statistics; Organisation and Implementation of Cancer Clinical Trials; Palliative Cancer Care; Translational Research in Clinical Trials; Basic Principles of Immunotherapy; Developing and Using Quality of Life Instruments in Clinical Trials; Psycho-Oncology; Basic Principles of Radiotherapy; Statistics in Medicine.

Selected-Awards and Honors

- 1995 Merit scholarship, University of Rome "Sapienza", Italy.
- 1998 Graduated with Honors (cum Laude), University of Rome "Sapienza", Italy.
- 2001 European Organisation for Research and Treatment of Cancer (EORTC) *Lady Grierson Quality of Life Research Fellowship Award*.
- 2005 International Society for Quality of Life Research (ISOQOL). *New Investigator Award*.
- 2006 *Visiting Professor*. Memorial Sloan-Kettering Cancer Center (MSKCC). New York, USA
- 2007 International Society for Quality of Life Research (ISOQOL). *New Investigator Award*
- 2010-present *Chairman* of the GIMEMA Working Party on Quality of Life
- 2010 European Hematology Association (EHA). *Travel Grant Winner*
- 2010 Member of the "Scientific Board" of the "Italian Group for Adult Hematologic Disease" (GIMEMA)
- 2012 Chair of the 19th Annual Conference of the *International Society for Quality of Life Research* Conference. Budapest (Hungary). 24-27 October, 2012
- 2010-2013 Member of the "Board of Directors" of "International Society for Quality of Life Research" (ISOQOL).
- 2017-2018 Chair, European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group

Selected- Professional Service Activities

- 2003-2006 Faculty member, EORTC Data Center Education Office. Brussels, Belgium.
- 2003-2006 Member of the Protocol Review Committee of EORTC Data Center. Brussels, Belgium.
- 2005 Scientific Review Panel. *International Society for Quality of Life Research* Conference. San Francisco, (CA), USA.
- 2006 Organizing Committee. 15th Annual Conference of the *International Society for Quality of Life Research* Conference. Lisbon, (Portugal).
- 2006 Chair of the Symposium "The value of health-related quality of life parameters in predicting clinical outcomes in cardiology and oncology". *International Society for Quality of Life Research* Conference. Lisbon, Portugal.
- 2007-2013 *Secretary* of the EORTC Quality of Life Group.
- 2008 Moderator Poster session on "Quality of life, ethics, economics" of the 13th Congress of the *European Hematology Association (EHA)*, Copenhagen, Denmark.
- 2009-present Chairman of the "Italian Group for Adult Hematologic Diseases" (GIMEMA) Working Group on "Quality of Life and Symptoms".

- 2009 *Grant Reviewer for the EORTC Quality of Life Group*
- 2010 Chair of the workshop “Quality of life and late effects in hematologic malignancies” at 7th Annual Symposium of the European LeukemiaNet (ELN). Mannheim, Germany.
- 2010 Organizing Committee. 17th Annual Conference of the *International Society for Quality of Life Research* Conference. London, UK
- 2010 Chair of the Organizing Committee of the *EORTC Quality of Life Group Meeting*, Rome (Italy).
- 2010-2013 Board of Directors of the *International Society for Quality of Life Research*.
- 2011 *Grant Review Committee Member* for the National Cancer institute of France (INCa). AERES Committees –Cancerpoles, Paris,
- 2014 *Grant reviewer* for EORTC Quality of Life Group
- 2015 Chair, Oral session on “*Quality of life, ethics, economics*” of the 20th Congress of the *European Hematology Association (EHA)*, Wien, Austria.
- 2015 Chair, Selection Committee “*Quality of life, ethics, economics*” of the 20th Congress of the *European Hematology Association (EHA)*, Wien, Austria.
- 2015 Chair, *Grant Review Committee* for the National Cancer institute of France (INCa). “Research Projects in Social and Human Sciences, Epidemiology and Public Health. May 2015

Editorial Activities

Ad hoc Reviewer for:

- Journal of Clinical Oncology (JCO)
- The Lancet Oncology (TLO)
- Journal of the National Cancer Institute (JNCI)
- Blood
- Annals of Oncology
- Value in Health
- Oncology
- Quality of Life Research
- Annals of Surgery
- Journal of Psychosomatic Research
- Journal of Geriatric Oncology
- Leukemia & Lymphoma
- Leukemia Research
- Lung Cancer
- Psycho-Oncology
- The Journal of Supportive Oncology
- Current Medical Research and Opinion
- Journal of the Society for Integrative Oncology
- Patient Education and Counselling
- International Journal of Surgical Oncology
- ISRN Oncology
- Journal of Cancer Research and Clinical Oncology
- Head & Neck
- Expert Review of Clinical Pharmacology
- Cancer Treatment Reviews
- JCO Clinical Cancer Informatics
- Journal of the American Medical Association (JAMA)
- British Medical Journal (BMJ)
- Leukemia
- Critical Reviews in Oncology/Hematology
- British Journal of Cancer (BJC)
- The Journal of Clinical Psychiatry
- Bone Marrow Transplantation
- European Journal of Cancer
- Critical Reviews in Oncology/Hematology
- Gynaecologic Oncology
- BMC Cancer
- European Journal of Haematology
- Psychological Bulletin
- Age and Ageing
- Leukemia Research and Treatment
- Mediterranean Jour of Hematol. and Infectious Diseases
- Cancer Therapy
- European Journal of Oncology Nursing
- Health and Quality of Life Outcomes
- Exp Rev. of Pharmacoeconomics & Outcomes Research
- Cochrane Colorectal Cancer Group (*protocol reviewer*)
- Expert Reviews of Quality of Life in Cancer Care
- European Respiratory Journal
- Nature Reviews Clinical Oncology
- Expert Review of Quality of Life in Cancer Care
- Haematologica
- Clinical Lymphoma, Myeloma and Leukemia

Associate Editor: Health and Quality of Life Outcomes (HQLO) Journal (<http://hqlo.biomedcentral.com/>)

Editorial Board:

- Blood,
- Expert Reviews of Quality of Life in Cancer Care;
- Open Journal of Hematology.

Selected invited presentations

14th International Symposium on Myelodysplastic Syndromes. MDS Foundation, (Plenary Session). "Health-related quality-of-life assessment in patients with myelodysplastic syndromes". Valencia, (Spain). (May, 2017).

American Society of Hematology (ASH), 58th Annual Congress. "The Value of Quality of Life Assessment in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors". Education Session on Chronic Myeloid Leukemia. San Diego (CA), USA (December, 2016)

Guangdong Medical University, School of Humanities and Management Dongguan, China. 6th Asian-Chinese Quality of Life Conference. "Integrating Patient-Reported Outcomes into Healthcare Research: Challenges and Opportunities". Dongguan, China. (May 2016).

Annual Meeting of the Chronic Myeloid Leukemia (CML) Advocates Network. *CML Horizons 2013*. "Patient versus Physician toxicity in CML patients receiving Tyrosine kinase inhibitors". Prague, Czech Republic, (May, 2013).

11th International Symposium on Myelodysplastic Syndromes. MDS Foundation, (Plenary Session). Edinburgh, (Scotland). "The added value of quality-of-life and other patient-reported outcomes in clinical research of patients with Myelodysplastic Syndromes". (May, 2011).

National Cancer Institute of France. "The prognostic value of quality of life in oncology: a meta analysis". Paris, France, (June, 2010).

European Leukemia-Net (ELN). 7th Annual Symposium. "Long-term patient-reported quality of life and symptoms in chronic myeloid leukemia patients treated with Imatinib". Mannheim, Germany, (February, 2010).

European Hematology Association (EHA) 14th Congress. Educational Session. *Designing and interpreting quality-of-life and other patient-reported outcomes in clinical trials*. Berlin, Germany, (June, 2009).

European Organisation for Research and Treatment of Cancer (EORTC) Leukemia Group Meeting. "The prognostic value of patient-reported health-status data in oncology". Rome, Italy. (April, 2008).

European Leukemia-Net (ELN). 5th Annual Symposium. "Prognostic significance and longitudinal assessment of patient-reported quality of life and symptoms in high-risk myelodysplastic syndromes". Heidelberg, Germany (January, 2008).

Italian Society of Psycho-oncology. 10th Annual Conference. "Health-related quality of life and satisfaction with care as outcome measures in oncology". Turin, Italy. (October, 2007).

European Hematology Association (EHA) 12th Congress. *Working Group on Quality of Life and Symptoms*. Quality of life and symptom measures in hematologic diseases". Wien, Austria (June, 2007).

University of Rome "La Sapienza". Department of Hematology. "The added value of measuring health-related quality of life in cancer clinical practice and clinical research", Rome, Italy. (January, 2007).

University of Padova. Department of Oncology. "Lessons learned from measuring health-related quality of life in colorectal cancer patients". Padova, Italy. (September, 2006).

Memorial Sloan-Kettering Cancer Center. Department of Surgery and Department of Psychiatry and Behavioural Sciences. "Patient's self-reported health status data and quality of life parameters: a guide for clinical decision-making in clinical practice". New York, USA (March 2006).

University of Leuven. Department of Psychology. "Psychosocial well-being, health behaviors and quality of life parameters in oncology". Leuven, Belgium (March 2006).

State University of New York at Stony Brook. Department of Psychiatry and Behavioral Sciences. "The use of patient's self reported quality of life outcomes as prognostic factors for clinical endpoints: challenges and recent findings". Stony Brook, Long Island, New York, USA (February 2006)

European School of Oncology. "Impact of Complementary and Alternative Medicine on the quality of life of cancer patients". Brussels, Belgium (February 2006).

University of Pittsburgh. Department of Psychology. "Quality of Life in cancer patients: measurement and clinical utility". Pittsburgh (PA), USA, (April, 2005).

Plenary Session of the European Organisation for Research and Treatment of Cancer (EORTC) Groups' Annual Meeting (EGAM), "Is quality of life a prognostic factor?". Brussels, Belgium, (March 2005).

World Psychiatric Association Conference. "The value of self-rating questionnaires in research of mental healthcare in oncology". Wien, Austria (June 2003).

PUBLICATIONS (15 most representative ones highlighted in yellow)

Peer-reviewed articles (full length manuscripts); currently more than 145 records in PubMed

van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, **Efficace F**; EORTC Quality of Life Group. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. *Qual Life Res*, [Epub ahead of print], 2017

Efficace F, Gaidano G, Lo-Coco F. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? *Blood*, 130(7):859-866, 2017.

Goel S, Paoli C, Iurlo A, Pereira A, **Efficace F**, Barbui T, Tefferi A, Vannucchi AM, Cervantes F. Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. *Eur J Haematol*, 99(1):36-41, 2017.

Breccia M, Baccarani M, Rosti G, Cottone F, Cannella L, Guilhot F, Vignetti M, **Efficace F**. Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. *Health Qual Life Outcomes*, 15(1):204, 2017

van Leeuwen M, Kieffer JM, **Efficace F**, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer

Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group. International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. *Health Qual Life Outcomes*, 15(1):97, 2017.

Giesinger JM, Aaronson NK, Arraras JL, **Efficace F**, Groenvold M, Kieffer JM, Loth FL, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B; EORTC Quality of Life Group. A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important. *Psychooncology*, [Epub ahead of print], 2017

Ahmed K, Kyte D, Keeley T, **Efficace F**, Armes J, Brown JM, Calman L, Copland C, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor R, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M. Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. *BMJ Open*, 21;6(9):e012863, 2016.

Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, Rosti G, Baccarani M. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. *Supportive Care in Cancer*. 2016 Jul 23. [Epub ahead of print]

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, **Efficace F**, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. *J Clin Oncol*, 35(6):605-612, 2017.

Bonnetain F, Fiteni F, **Efficace F**, Anota A. Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. *Journal of Clinical Oncology*. 2016 Jun 1;34(16):1953-6.

Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. *Am J Hematol*, 91(10):995-1001, 2016.

Abel GA, **Efficace F**, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). *Haematologica*, 101(6):781-8, 2016.

Mercieca-Bebber RL, Perreca A, King M, Macann A, Whale K, Soldati S, Jacobs M, **Efficace F**. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation. *European Journal of Cancer*, 56:144-61, 2016.

Gerritsen A, Jacobs M, Henselmans I, van Hattum J, **Efficace F**, Creemers GJ, de Hingh IH, Koopman M, Molenaar IQ, Wilmink HW, Busch OR, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group. Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey. *European Journal of Cancer*, 57:68-77, 2016.

Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, Iurlo A, Russo Rossi A, Luciano L, Martino B, Galimberti S, Turri D, Bergamaschi M, Tiribelli M, Fava C, Angelucci E, Mandelli F, Baccarani M. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. *Annals of Hematology*, 95(2):211-9, 2016.

Sodergren SC, Copson E, White A, **Efficace F**, Sprangers M, Fitzsimmons D, Bottomley A, Johnson CD. Systematic Review of

the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group. *Targeted Oncology*, 11(3):277-92, 2016.

Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. *The Lancet Oncology*, 16(15):1506-14, 2015.

Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, Maggi A, Falzetti F, Capalbo SF, Intermesoli T, Maffioli M, Elena C, Melosi A, Simonetti F, Capochiani E, Seta RD, Pacilli M, Luppi M, Di Renzo N, Mastrullo L, Trabacchi E, Vallisa D, Rapezzi D, Orlandi EM, Gambacorti-Passerini C, **Efficace F**, Alimena G. Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. *Support Care Cancer*, 24(11):4487-93, 2016.

Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, **Efficace F**. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? *Critical Reviews in Oncology/Hematology*, 1040-8428(15)30012-3, 2015.

Breccia M, **Efficace F**, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. *Leukemia Research*, 39(10):1055-9, 2015.

Kyte D, Reeve BB, **Efficace F**, Haywood K, Mercieca-Bebber R, King MT, Norquist JM, Lenderking WR, Snyder C, Ring L, Velikova G, Calvert M. International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. *Quality of Life Research*, 25(2):359-62, 2016.

Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, **Efficace F**. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. *Leukemia Research*, 39(8):859-65, 2015.

Efficace F, Fayers P, Pusic A, Cemal Y, Yanagawa J, Jacobs M, la Sala A, Cafaro V, Whale K, Rees J, Blazeby J; Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. *Cancer*, 121(18):3335-42, 2015.

Gilbert A, Ziegler L, Martland M, Davidson S, **Efficace F**, Sebag-Montefiore D, Velikova G. Systematic Review of Radiation Therapy Toxicity Reporting in Randomized Controlled Trials of Rectal Cancer: A Comparison of Patient-Reported Outcomes and Clinician Toxicity Reporting. *International Journal of Radiation Oncology, Biology, Physics*, 92(3):555-67, 2015.

Feuerstein MA, Jacobs M, Piciocchi A, Bochner B, Pusic A, Fayers P, Blazeby J, **Efficace F**; Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. *Urologic Oncology*, 33(7):331.e17-23, 2015.

Rees JR, Whale K, Fish D, Fayers P, Cafaro V, Pusic A, Blazeby JM, **Efficace F**. Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making. *Journal of Cancer Research and Clinical Oncology*, 141(12):2181-92, 2015.

Brédart A, Kop JL, **Efficace F**, Beaudeau A, Brito T, Dolbeault S, Aaronson N; EORTC Quality of Life Group. Quality of care in

the oncology outpatient setting from patients' perspective: a systematic review of questionnaires' content and psychometric performance. *Psychooncology*, 24(4):382-94, 2015..

Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. *British Journal of Hematology*, 68(3):361-70, 2015.

Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. *Journal of Clinical Oncology*, 32(30):3406-12, 2014.

Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. *BMJ Supportive and Palliative Care*, Sep 9. pii: bmjcare-2014-000726, 2014.

Pisu S, Caocci G, d'Aloja E, **Efficace F**, Vacca A, Piras E, Orofino MG, Addari C, Pintor M, Demontis R, Demuru F, Pittau MR, Collins GS, La Nasa G. Reassessing the approach to informed consent: the case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients. *Philosophy, Ethics, and Humanities in Medicine*, 12;9:13, 2014.

Dirven L, Taphoorn MJ, Reijneveld JC, Blazeby J, Jacobs M, Pusic A, La Sala E, Stupp R, Fayers P, **Efficace F**; The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. *European Journal of Cancer*, 50(14):2432-48, 2014

Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F. Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. *Annals of Oncology*, 25(2):447-54, 2014.

Efficace F, Jacobs M, Pusic A, Greimel E, Piciocchi A, Kieffer JM, Gilbert A, Fayers P, Blazeby J; Patient-reported outcomes in randomised controlled trials of gynaecological cancers: Investigating methodological quality and impact on clinical decision-making. *European Journal of Cancer*, 50(11):1925-1941, 2014.

Efficace F, Rosti G, Cottone F, Breccia M, Castagnetti F, Iurlo A, Mandelli F, Baccarani M. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. *Leukemia Research*, 38(3):294-8, 2014.

Efficace F, Rees J, Fayers P, Pusic A, Taphoorn M, Greimel E, Reijneveld J, Whale K, Blazeby J; Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry. *Health and Quality of Life Outcomes*, Jun 6;12:86, 2014.

van Leeuwen M, **Efficace F**, Fosså SD, Bolla M, De Giorgi U, de Wit R, Holzner B, van de Poll-Franse LV, van Poppel H, White J, Collette L, Osanto S2, Aaronson NK. Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities. *European Journal of Cancer*, Jul;50(11):1957-63. doi: 10.1016/j.ejca.2014.04.018

Sodergren SC, White A, **Efficace F**, Sprangers M, Fitzsimmons D, Bottomley A, Johnson CD. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the

EORTC Quality of Life Group. *Critical Review in Oncology and Hematology*, 91(1):35-46, 2014.

Efficace F, Feuerstein M, Fayers P, Cafaro V, Eastham J, Pusic A, Blazeby J. EORTC Quality of Life Group (Patient Reported Outcome Measurements Over Time In ONcology-PROMOTION Project). Patient-Reported Outcomes In Randomized Controlled Trials of Prostate Cancer: Methodological Quality and Impact on Clinical-Decision-Making. *European Urology*, (in press) 2013.

Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, **Efficace F**. The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. *Health and Quality of Life Outcomes*, Oct 29;11:184, 2013.

Efficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S, Vignetti M, Mandelli F, Bacarani M. Patient versus Physician Symptom and Health Status Reporting in Chronic Myeloid Leukemia. *Haematologica*, 99(4):788-93, 2014.

La Nasa G, Caocci G, **Efficace F**, Dessì C, Vacca A, Piras E, Sanna M, Marcias M, Littera R, Carcassi C, Lucarelli G. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. *Blood*, 122(13):2262-70, 2013.

Alonso J, Bartlett SJ, Rose M, Aaronson NK, Chaplin JE, **Efficace F**, Leplège A, Lu A, Tulsy DS, Raat H, Ravens-Sieberer U, Revicki D, Terwee CB, Valderas JM, Cella D, Forrest CB; PROMIS International Group. The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative. *Health and Quality of Life Outcomes*, Dec 20;11:210, 2013.

Efficace F, Bacarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. *Quality of Life Research*, 23(3):825-836, 2014.

Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA*, 309(8):814-22, 2013. (Collaborator: **Efficace F**).

Cottone F, **Efficace F**, Apolone G, Collins GS. The added value of Propensity score matching when using health-related quality of life reference data. *Statistics in Medicine*, 32(29):5119-32, 2013.

Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. *Leukemia Research*, 37(2):206-213, 2013.

Efficace F, Bacarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. *Leukemia*, 27(7):1511-9, 2013.

Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, **Efficace F**, King M, Lam CL, Moher D, Scott J, Sloan J, Snyder C, Yount S, Calvert M. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. *Quality of Life Research*, 22(6):1161-75, 2013.

Efficace F, Bacarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. *British Journal of Cancer*, 107(6):904-909, 2012.

Efficace F, Cartoni C, Niscola P, Tendas A, Meloni E, Scaramucci L, Soldati S, Brunetti GA, Marini MG, Mandelli F. Predicting

Survival in Advanced Hematologic Diseases: Do Patient-Reported Symptoms Matter? *European Journal of Hematology*, 89(5):410-416, 2012.

Holzner B, **Effica F**, Basso U, Incrocci L, Johnson C, Aaronson N, Arraras J, King M, Chow E, Oberguggenberger A, Bottomley A, Steiner H, Giesinger J. Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: The EORTC QLQ-TC26. *Quality of Life Research*, 22(2):369-378, 2013

Cartoni C, Brunetti GA, Federico V, **Effica F**, Grammatico S, Tendas A, Scaramucci L, Cupelli L, D'Elia GM, Truini A, Niscola P, Petrucci MT. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. *Supportive Care in Cancer*, 20(10):2621-2626, 2012.

Caocci G, **Effica F**, Ciotti F, Roncarolo MG, Vacca A, Piras E, Littera R, Dawood Markous RS, Collins GS, Ciceri F, Mandelli F, Markt S, La Nasa G. Health related quality of life in Middle Eastern children with beta-thalassemia. *BMC Blood Disorders*, Jun 22;12(1):6, 2012

Niscola P, Tendas A, Cupelli L, Catalano G, Scaramucci L, Giovannini M, Trinchieri V, Sharma A, **Effica F**, Cartoni C, Piccioni D, Perrotti A, Dentamaro T, de Fabritiis P, Keefe DM. The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes. *Cardiovascular & Hematological Agents in Medicinal Chemistry*, 10(4):362-375, 2012.

Velikova G, Coens C, **Effica F**, Greimel E, Groenvold M, Johnson C, Singer S, van de Poll-Franse L, Young T, Bottomley A. Health-Related Quality of Life in EORTC clinical trials –30 years of progress from methodological developments to making a real impact on oncology practice. *European Journal of Cancer (Supplements)*, 10 (1): 141-149, 2012.

Effica F, Breccia M, Saussele S, Kossak U, Cardoni A, Caocci G, Chie W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti M, Baccarani M, Mandelli F, Sprangers M. Which Health-Related Quality of Life Aspects are important to patients with Chronic Myeloid Leukemia Receiving Targeted Therapies and to Health Care Professionals? GIMEMA and EORTC Quality of Life Group. *Annals of Hematology* 91(9):1371-81, 2012.

Niscola P, Tendas A, Giovannini M, Scaramucci L, Cupelli L, Ferrannini M, Brunetti GA, Bondanini F, Palumbo R, Perrotti A, Romani C, Cartoni C, **Effica F**, de Fabritiis P. Pain management in hematological patients with major organ dysfunctions and comorbid illnesses. *Cardiovascular & Hematological Agents in Medicinal Chemistry*, 10(2):135-147, 2012.

Vivat B, Young T, **Effica F**, Sigurðadóttir V, Arraras J, Ásgeirsdóttir G, Brédart A, Costantini A, Kobayashi K, Singer S. Cross-cultural development of the EORTC QLQ-SWB36: A stand-alone measure of spiritual wellbeing for palliative care patients with cancer. *Palliative Medicine*, 27(5):457-469, 2013.

Weis J, Bottomley A, Flechtner H, **Effica F**, Lanceley A, Görög A, Jones L, Holzner B, Hammerlid E, Arraras J, Singer S, Conroy T, Wirtz M, Fleissner C. Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13). *Psycho-oncology*, 22(5):1002-1007, 2013.

Effica F, Taphoorn M. Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies. *Journal of Neuro-oncology*, 108(2):221-6, 2012.

Chow E, Nguyen J, Zhang L, Tseng LM, Hou MF, Fairchild A, Vassiliou V, Jesus-Garcia R, Alm El-Din MA, Kumar A, Forges F, Chie WC, Bottomley. International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. *Cancer*, 118(5):1457-1465, 2012. (Collaborator: **Effica F**).

Niscola P, Tendas A, Giovannini M, Cupelli L, Trawinska MM, Palombi M, Scaramucci L, Brunetti GA, Perrotti A, Neri B, **Effica F**, Cartoni C, de Fabritiis P, Mandelli F. Transfusions at home in patients with myelodysplastic syndromes. *Leukemia Research*,36(6):684-688, 2012.

Effica F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, Baccarani M, Mandelli F. Time for a new era in the

evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes. *Critical Reviews in Oncology/Hematology*, 81(2):123-35, 2012.

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. *Blood*, 118(17):4554-4560, 2011.

Caocci G, **Efficace F**, Ciotti F, Roncarolo MG, Vacca A, Piras E, Littera R, Dawood Markous RS, Collins GS, Ciceri F, Mandelli F, Markt S, La Nasa G. Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation. *Biology of Bone and Marrow Transplantation*, 7(6):861-866, 2011.

Pucciarelli S, Del Bianco P, **Efficace F**, Serpentine S, Capirci C, De Paoli A, Amato A, Cuicchi D, Nitti D. Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. *Annals of Surgery*, 253(1):71-77, 2011

Breccia M, **Efficace F**, Alimena G. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? *Cancer Letters* 300(2):115-1521, 2011.

Pucciarelli S, Del Bianco P, **Efficace F**, Toppan P, Serpentine S, Friso ML, Lonardi S, De Salvo GL, Nitti D. Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. *Supportive care in Cancer* 18(5):601-608, 2010.

Tuveri M, Caocci G, **Efficace F**, Medas F, Collins G, Pisu S. Different perception of surgical risks between physicians and patients undergoing laparoscopic cholecystectomy. *Surgical Laparoscopy Endoscopy & Percutaneous Techniques*, 19(4):305-311, 2009.

Caocci G, La Nasa G, **Efficace F**. Health-related quality of life and symptom assessment in clinical research of patients with myelodysplastic syndromes. *Expert Review of Hematology*, 2(1), 69-80, 2009.

Van Andel G, Bottomley A, Fosså S, **Efficace F**, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, D'haese S, Aaronson NK. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. *European Journal of Cancer*, 44(16), 2418-2424, 2008.

Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukemia randomized controlled trials. A systematic review to evaluate the added value in supporting clinical decision-making. *European Journal of Cancer*, 44(11), 1497-1506, 2008.

Pucciarelli S, Del Bianco P, Toppan P, Serpentine S, **Efficace F**, Pasetto LM, Friso ML, De Salvo GL, Nitti D. Health-related quality of life outcomes in disease-free survivors of mid-low rectal cancer after curative surgery. [Annals of Surgical Oncology](#), 15(7), 1846-1854, 2008.

Efficace F, Innominato P, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients. Results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. *Journal of Clinical Oncology* 26(12), 2020-2026, 2008.

Gotay C, Kawamoto CT, Bottomley A, **Efficace F**. The Prognostic significance of patient-reported outcomes in cancer clinical trials. *Journal of Clinical Oncology*, 26(8), 1355-1363, 2008.

Bottomley A, Coens C, **Efficace F**, Gaafar R, Manegold C, Burgers S, Vincent M, Giaccone G, van Meerbeeck J. Symptom and patient-reported wellbeing: do they predict survival in Malignant Pleural Mesothelioma: A joint international study of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Unit and Lung Cancer Group. *Journal of Clinical Oncology*, 25(36), 5770-5776, 2007.

Mauer M, Taphoorn MJB, Bottomley A, Coens C, **Efficace F**, Sanson M, Brandes AA, van der Rijt CCD, Bernsen HJJA, Frenay M, Tijssen CC, Lacombe D, van den Bent MJ. The prognostic value of health-related quality of life data in predicting survival in anaplastic oligodendrogliomas cancer patients: results from an international randomized phase III EORTC Brain Cancer Group study. *Journal of Clinical Oncology*, 25(36), 5731- 5737, 2007.

Byrne C, Griffin A, Blazeby J, Conroy T, **Efficace F**. Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer. *European Journal of Surgical Oncology* 33S2:S95-104, 2007.

Mauer M, Stupp R, Taphoorn MJB, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, **Efficace F**, Mirimanoff RO, Forsyth P, van den Bent MJ, Weller M, Bottomley A, The prognostic value of health-related quality of life data in predicting survival in glioblastoma cancer patients: results from an EORTC BTG, ROG, and NCIC international randomized phase III study. *British Journal of Cancer* 97(3), 302-307, 2007.

Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. *Annals of Oncology* 18(4), 775-781, 2007.

Brédart A, Coens, Aaronson N, Chie W, **Efficace F**, Conroy T, Blazeby J, Hammerlid E, Costantini M, Joly F, Schraub S, Sezer O, Arraras J, Rodary C, Costantini A, Mehlitz M, Razavi D, Bottomley A. Determinants of patient satisfaction in oncology settings from European and Asian countries: Preliminary results based on the EORTC IN-PATSAT32 questionnaire. *European Journal of Cancer* 43(2), 323-330, 2007.

Arraras J, Kuljanic-Vlasic K, Bjordal K, Yun YH, **Efficace F**, Holzner B, Mills J, Greimel E, Velikova G, Kraub O. An EORTC questionnaire to assess information given to cancer patients: a preliminary analysis in eight countries. *Psycho-Oncology* 16(3), 249-254, 2007

Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck. Is a patient's self-reported health related quality of life a prognostic factor for survival in non-small-cell-lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. *Annals of Oncology* 17(11), 1698-1704, 2006.

Efficace F, Horneber M, Lejeune S, Van Dam F, Leering S, Rottmann M, Aaronson NK. Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. *Journal of Clinical Epidemiology* 59(12), 1257-1265, 2006.

Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne CH. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? *European Journal of Cancer* 42(1), 42-49, 2006.

Brédart A, Bottomley A, Blazeby J, Conroy T, Coens C, D'haese S, Chie W, Hammerlid E, Arraras J, **Efficace F**, Rodary C, Schraub S, Costantini M, Costantini A, Joly F, Sezer O, Razavi D, Mehlitz M, Bielska-Lasota M, Aaronson NK. An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT 32). *European Journal of Cancer* 41(14), 2120-2131, 2005.

Bottomley A, Flechtner H, **Efficace F**, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E. On behalf of the European Organisation for Research And Treatment of Cancer (EORTC) Data Center and Quality of Life Group. Health-related

quality of life outcomes in cancer clinical trials. *European Journal of Cancer* 41(12), 1697-1709, 2005.

Bottomley A, Therasse P, Piccart MJ, **Efficace F**, Coens C, Gotay C, Welnicka –Jaskiewicz M, Mauriac L, Dyczka J, Cufer T, Lichinitser M, Schornagel JH, Bonnefoi H, Shepherd L. Health-related quality of life in survivors of locally advanced breast cancer: an international randomized controlled phase III trial. *The Lancet Oncology* 6(5), 287-294, 2005.

D'haese S, Bate T, Claes S, Boone A, Vanvoorden V, **Efficace F**. Management of Skin Reactions During Radiotherapy: A Study of Nursing Practice. *European Journal of Cancer Care* 14(1), 28-42, 2005.

Efficace F, Therasse P, Piccart M, Coens C, Van Steen K, Welnicka-Jaskiewicz M, Cufer T, Dyczka J, Lichinitser M, Shepherd L, de Haes H, Sprangers MA, Bottomley A. Health-related quality of life parameters as prognostic factors in a non-metastatic breast cancer population. An international multicenter study. *Journal of Clinical Oncology* 22(16), 3381-3388, 2004.

Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, **Efficace F**, Calvert AH, Gamucci T, Twelves C, Fargeot P, Piccart M. Randomized controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group; Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. *Journal of Clinical Oncology* 22(13), 2576-2586, 2004.

Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A. EORTC-BCG-IDBBC-NDDG. Baseline health-related quality of life data as prognostic factors in a phase III multicenter study of women with metastatic breast cancer. *European Journal of Cancer* 40(7), 1021-1030, 2004.

Efficace F, Bottomley A, Vanvoorden V, Blazeby JM. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials. *European Journal of Cancer*, 40(2), 187-197, 2004.

Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, Zurlo A. Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision-making? *Journal of Clinical Oncology* 21(18), 3502-3511, 2003.

Bottomley A, **Efficace F**, Thomas R, Vanvoorden V, Ahmedzai S. Health-related quality of life in non small-cell lung cancer: methodologic issues in randomized controlled trials. *Journal of Clinical Oncology* 21(15), 2982-2992, 2003.

Efficace F, Bottomley A, van Andel G. Health-related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. *Cancer* 97(2), 377-388, 2003.

D'haese S, Bottomley A, **Efficace F**. External beam radiotherapy in prostate cancer patients: short and long-term health related quality of life issues. *Expert Review of Pharmacoeconomics & Outcomes Research* 3(4), 487-495, 2003.

Efficace F, Bottomley A. Health-related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. *European Journal of Cancer* 38(14), 1824-1831, 2002.

Efficace F, Bottomley A, Collins G. Quality of life in breast cancer patients: measurement issues in cancer clinical trials. *Expert Review of Pharmacoeconomics & Outcomes Research*, 2(1), 57-65, 2002.

Efficace F, Marrone R. Spiritual issues and quality of life assessment in cancer care. *Death Studies* 26(9), 743-756, 2002.

Collins G, **Efficace F**. Cultural issues in assessing quality of life in cancer clinical trials. *Expert Review of*

Pharmacoeconomics & Outcomes Research 2(3), 261-267, 2002.

Caruso A, **Efficace F**, Parrila A, Ferranti F, Angelone L, Grandinetti ML. Pain and anxiety related to mammography in breast cancer patients. Psychological evaluation in an experimental study. *La Radiologia Medica*, 102(5-6), 335-339, 2001.

Efficace F. L'ipnosi cent'anni dopo Freud: considerazioni teoriche sulla moderna psicoterapia ipnotica e sulle sue implicazioni nei processi di guarigione. *Psicoterapia e Scienze Umane*, 35(1), 105-116, 2001.

Efficace F. Esperienze di morte e trasformazione in Carl Gustav Jung. *Informazione in Psicologia, Psicoterapia e Psichiatria*, 10/11(38-39), 64-69, 2000.

Efficace F. L'ipnosi in una prospettiva psicobiologica e il suo ruolo nella cura dei pazienti oncologici. *Rivista Italiana di Ipnosi e Psicoterapia Ipnologica*, 20(4), 105-109, 2000.

Efficace F. Considerazioni sull'essenza della psicoterapia ipnotica. *Rivista Italiana di Ipnosi e Psicoterapia Ipnologica*, 19(2), 43-46, 1999.

Efficace F. Stati modificati di coscienza e psicoterapia ipnotica: una discussione. *Rivista Italiana di Ipnosi e Psicoterapia Ipnologica*, 19(3), 61-65, 1999.

Carotenuto A, **Efficace F**. L'ingenua premessa dell'unità della coscienza: il concetto di dissociazione in Carl Gustav Jung e le sue implicazioni con la moderna psicoterapia ipnotica. *Attualità in Psicologia*, 14(2), 161-166, 1999.

Efficace F. Considerazioni teoriche sulle relazioni tra ipnosi, autoipnosi e dissociazione. *Psicologia Europea*, 11(1), 53-56, 1999.

Efficace F. Le discontinuità della coscienza in relazione ai disturbi dissociativi. *Rivista Europea di Psichiatria*, 11(1), 25-28, 1999.

Editorials/Letters

Breccia M, **Efficace F**. Are chronic myeloid leukemia patients ready to stop long-term treatment? *Leuk Lymphoma*, 58(12):2976-2978, 2017.

Bonnetain F, **Efficace F**, Fiteni F, Anota A. Reply to B. Kurland et al. *J Clin Oncol*, 34(36):4450-4451, 2016.

Efficace F, Cannella L, Cottone F Pushing the boundaries of care in myelodysplastic syndromes: Physical exercise to improve fatigue and health-related quality of life outcomes. *Leukemia Research*, 9;49:36-37, 2016

Nicola P, Mandelli F, **Efficace F**. Improving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models. *Expert Review of Hematology*, 9(5):415-7, 2016.

Breccia M, **Efficace F**. Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough? *Current Medical Research and Opinion*, 32(8):1453-4, 2016.

Nicola P, Siniscalchi A, Tendas A, de Fabritiis P, Caravita T, **Efficace F**. Towards a better understanding of the relationship

between side effects of analgesia and quality of life in patients with multiple myeloma. *Supportive Care in Cancer*, 24(1):9-10, 2016.

Efficace F, Mandelli F, Platzbecker U, Cottone F, Lo Coco F. Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia. *Blood*, 126(22):2523-4, 2015.

Efficace F, Cottone F, Lo-Coco F. Reply to M. Koehler et al. *Journal of Clinical Oncology*. 20;33(9):1091-2, 2015.

Breccia M, Molica M, **Efficace F**, Minotti C, Latagliata R, Foà R, Lo Coco F. Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. *British Journal of Hematology*. 2014 Jun 24. doi: 10.1111/bjh.12995

Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, **Efficace F**. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. *Blood*, 123(3):451-2, 2014.

Efficace F, Breccia M, Lo Coco F. Patient-reported outcomes in acute leukemia: a roadmap for future research. *European Journal of Hematology*. 93(1):86-7, 2014.

Baccarani M, **Efficace F**, Rosti G. Moving Towards Patient-Centered Decision-Making in Chronic Myeloid Leukemia: Assessment of Quality of Life and Symptom Burden. *Haematologica*, 99(2):205-8, 2014.

Efficace F, Lo-Coco F. Using patient-reported health status to improve prognostic assessment in patients with acute myeloid leukemia: current challenges and future applications. *Haematologica* 98(1):7-9, 2013.

Breccia M, **Efficace F**, Alimena G. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf? *Leukemia Research*, 36(7):813-4, 2012.

Breccia M, **Efficace F**, Alimena G. Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. *Leukemia Research*, 36(7):804-5, 2012.

Scaramucci L, Tendas A, Niscola P, Bondanini F, Giovannini M, Palombi M, Cupelli L, **Efficace F**, Perrotti A, de Fabritiis P. Motor disability in the setting of oral anticoagulant therapy. *International Journal of Hematology*, 94(5):499-500, 2011.

Legrand C, **Efficace F**. Implementing patient-reported health-related quality-of-life data in cancer routine practice to improve accuracy of prognosis. Are we there yet? *Expert Review of Pharmacoeconomics & Outcomes Research* 9(6):493-6, 2009.

Efficace F, Vignetti M, Mandelli F. Asking patients with hematological malignancies: 'how do you feel?' Does it really provide independent prognostic information for survival? *European Journal of Hematology* 82(6), 484-5, 2009.

Efficace F, Novik A, Vignetti M, Mandelli F, Cleeland CS. Health-related quality of life and symptom assessment in clinical research of patients with haematological malignancies: where are we now and where do we go from here? *Haematologica* 92(12), 1596-1598, 2007.

Bottomley A, **Efficace F**. Predicting survival in advanced cancer patients: is it possible with patient reported health status data? *Annals of Oncology* 17(7), 1037-8, 2006.

Coens C, Bottomley A, **Efficace F**, Flechtner H, Aaronson NK. Variability and sample size requirements for health-related quality of life measures: understanding the challenges facing investigators. *Journal of Clinical Oncology* 23(33), 8541-2, 2005.

Efficace F, Bottomley A. Toward a clearer understanding of the prognostic value of health-related quality of life (HRQOL) parameters in breast cancer. *Journal of Clinical Oncology* 23(6), 1335-6, 2005.

Efficace F, Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. *The Lancet Oncology* 4(1), 11-12, 2003.

Efficace F, Bottomley A, Blazeby JM. Randomized clinical trial comparing quality of life after straight and pouch coloanal reconstruction (Br J Surg 2003; 89: 1108-1117). *British Journal of Surgery* 90(5), 594-595, 2003.

Efficace F, Bottomley A. Do quality of life randomized clinical trials support clinicians in their decision-making? *Journal of Clinical Oncology* 20(19), 4126-4127, 2002.

Bottomley A, **Efficace F**, Fayers PM. Standards are needed for quality of life clinical trials. *British Medical Journal*, 324 (7346), 1156, 2002.

Book / Chapter book

Efficace F, Cannella L. *The Value of Quality of Life Assessment in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors*. Education Program 2016, for the 58th Congress of the American Society of Hematology (ASH). San Diego (CA), USA. Educational Book. 2016(1):170-17, 2016

Holzner B, Giensinger J, **Efficace F**: The value of quality of life assessment in cancer patients, in Wise T, Biondi M, Costantini A (eds): *Psycho-Oncology*. Washington DC, USA. American Psychiatric Publishing. pp. 259-287, 2013.

Efficace F. *“Qualità di vita”*. ‘Enciclopedia Treccani “XXI Secolo” (Vol. “Il Corpo e la Mente”), Edizioni Istituto Enciclopedia Treccani, Roma 2010.

Efficace F, Sprangers M. *Designing and interpreting quality-of-life and other patient-reported outcomes in clinical trials*. Education Program for the 14th Congress of the European Hematology Association (EHA). Berlin, Germany. Educational Book; pp.89-95, 2009.

Efficace F, Biganzoli L: *Prognostication in Breast cancer*, in Glare P and Christakis N (eds): *Prognosis in Advanced Cancer*. New York, Oxford University Press. Pp. 123-133, 2008.

Efficace F. *The value of health-related quality of life assessment in cancer clinical trials*. Dutch University Press (ISBN 90-3619-032-0). PhD thesis. Amsterdam, The Netherlands. 2004.

Conference Presentations/Abstracts (not including abstracts submitted)

Efficace F, Niscola P, Gaidano G, Ricco A, Caocci G, Breccia M, Palumbo GA, Voso MT, Vallisa D, Allione B, Canicatti M, Okumura I, Cottone F, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Stauder R, Platzbecker U, Luppi M, Petranovic D, Caers J, Cascavilla N, Vignetti M, Mandelli F. Impact of Transfusion Dependency on Health-Related Quality of Life Outcomes in Newly Diagnosed Patients with Myelodysplastic Syndromes (MDS). Analysis on 669 Patients By Disease Risk. 59th ASH Annual Meeting, Atlanta, GA (USA), Dec 2017.), Blood, 130 (Suppl 1): 353, 2017.

Efficace F, Baccarani M, Stagno F, Iurlo A, Abruzzese E, Scaffidi L, Breccia M, Castagnetti F, Usala E, Crugnola M, Capodanno I, Martino B, Tiribelli M, Gaidano G, Bosi A, Luciano L, Pregno P, Cottone F, Tosi P, Cascavilla N, Binotto G, Saussele S, Fozza C, Bergamaschi M, Sancetta R, Caocci G, Rosti G. Health-Related Quality of Life and Symptom Burden in Chronic Myeloid Leukemia Patients Treated with First Line with Imatinib Versus Those Treated with Dasatinib: First Results of the Leonidas Study. 59th ASH Annual Meeting, Atlanta, GA (USA), Dec 2017. Blood, 130(Suppl 1): 3422, 2017.

Loth F, Holzner B, Aaronson N, Arraras J, **Efficace F**, Ramage J, Groenvold M, Kieffer J, Petersen M, Tomaszewski K, Young T, Giesinger J. Development of thresholds for clinical importance for the EORTC quality of life measures. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). Quality of Life Research, 26(1):31 (abs.202.5), 2017.

Deliu N, **Efficace F**, Collins G, Anota A, Bonnetain F, Van Steen K, Cella D, Cottone F. Modelling strategies to improve estimates of prognostic factors analyses with patient reported outcomes: a simulation study. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). Quality of Life Research, 26(1):34 (abs.204.2), 2017.

Cottone F, Anota A, Bonnetain F, **Efficace F**. Time to quality of life improvement as a method for longitudinal analysis of treatment efficacy. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). Quality of Life Research, 26(1):37 (abs.205.4), 2017.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci A, Zhang H, Sprangers M, Vignetti M, Mandelli F. The FA-IPSS(h): A New Index Combining Clinical Data and Patient-Reported Outcomes to Improve Prognostication for Myelodysplastic Syndromes. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). Quality of Life Research, 26(1):52 (abs.1003), 2017.

Kyte D, Retzer A, Keeley T, Ahmed K, Armes J, Brown J, Calman L, Copland C, **Efficace F**, Gavin A, Glaser A, Greenfield D, Lanceley A, Taylor R, Velikova G, Brundage M, Mercieca-Bebber R, King M, Calvert M. Systematic evaluation of Patient-Reported Outcome (PRO) protocol content and reporting in cancer clinical trials: the EPiC study. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). Quality of Life Research, 26(1):55 (abs.2005), 2017.

Sparano F, Rees J, Blazeby J, Pezold M, Pusic A, Aaronson N, Sprangers M, Fayers P, Deliu N, Anota A, **Efficace F**, On behalf of GIMEMA and EORTC Quality of Life Group. Patient-Reported Outcomes (PROs) in Randomized Controlled Trials of Colorectal Cancer. Methodological Quality of Reporting Over Time. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). Quality of Life Research, 26(1):65 (abs.1051), 2017.

Touraine C, Ousmen A, Deliu N, Cottone F, Bonnetain F, **Efficace F**, Bredart A, Bascoul-Mollevis C, Anota A. Statistical methods to determine the minimal clinically important difference in Health-Related Quality of Life questionnaires in cancer: a systematic literature review. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). Quality of Life Research, 26(1):101 (abs.2016), 2017.

Efficace F, Aaronson N, Sparano F, Sprangers M, Fayers P, Pusic A, Anota A, Cottone F, Rees J, Deliu N, Picocchi A, La Sala E, Haas A, Kieffer J, Wang W, Pezold M, Fuzesi S, Isharwal S, Yeung J, Wan C, Blazeby J, On behalf of GIMEMA and EORTC Quality of Life Group. Concordance between patient reported and clinical outcomes in randomized controlled trials (RCTs) of cancer

treatment. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). *Quality of Life Research*, 26(1):103 (abs.2026), 2017.

Efficace F, Aaronson N, Sparano F, Sprangers M, Fayers P, Pusic A, Haas A, Anota A, Cottone F, Deliu N, Rees J, Kieffer J, Wang W, Fuzesi S, Isharwal S, Yeung J, Wan C, Blazeby J, On behalf of GIMEMA and EORTC Quality of Life Group. Type and Magnitude of EORTC QLQ-C30 Outcomes in Cancer Clinical Trials. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). *Quality of Life Research*, 26(1):104 (abs.2030), 2017.

Anota A, Fiteni F, Cottone F, Pusic A, Sparano F, Fuzesi S, Bonnetain F, **Efficace F**. Investigating Methodology of Patient-Reported Outcomes Data Analysis in Breast Cancer Randomized Clinical Trials. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). *Quality of Life Research*, 26(1):117 (abs.3015), 2017.

Efficace F, Aaronson N, Sparano F, Sprangers M, Fayers P, Pusic A, Haas A, Piciocchi A, La Sala E, Anota A, Cottone F, Deliu N, Rees J, Kieffer J, Wang W, Pezold M, Fuzesi S, Isharwal S, Yeung J, Wan C, Blazeby J, On behalf of GIMEMA and EORTC Quality of Life Group. Quality of Patient-Reported Outcome (PRO) Reporting in Randomized Controlled Trials (RCTs) over time. Evidence from 480 RCTs from 2004 to 2016. 24th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Philadelphia (USA). *Quality of Life Research*, 26(1):139 (abs.3056), 2017.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci A, Zhang H, Sprangers M, Vignetti M, Mandelli F. Development and external validation of a new patient-centered prognostic index for patients with advanced myelodysplastic syndromes. 22nd Congress of the European Hematology Association (EHA), Madrid (Spain). *Haematologica* 2017; 102(s2):487. (abs. E1186)

Campinha-Bacote A, Trask P, **Efficace F**. The Prognostic Value for Survival of Patient-Reported Outcomes in Hematological Malignancies: A Systematic Review. 58th ASH Annual Meeting, San Diego, CA (USA). *Blood* Dec 2016, 128 (22): 4793.

Efficace F, Rosti G, Cottone F, Cannella L, Vignetti M, Mandelli F, Breccia M, Baccarani M. Physicians' Attitude Towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients. 58th ASH Annual Meeting, San Diego, CA (USA). *Blood* Dec 2016, 128 (22): 5939

Efficace F, Mandelli F, Borlenghi E, Breccia M, Rambaldi A, Specchia G, Rodeghiero F, Morselli M, Fabbiano F, Cantore N, Angelucci E, Caramatti C, Di Bartolomeo P, Pizzolo G, Vignetti M, Lo Coco F. Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy. 58th ASH Annual Meeting, San Diego, CA (USA). *Blood* Dec 2016, 128 (22): 2415

Efficace F, Niscola P, Cottone F, Gaidano G, Anota A, Bonnetain F, Caocci G, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Fedele M, Di Tucci A, Zhang H, Vignetti M, Mandelli M. Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. 58th ASH Annual Meeting, San Diego, CA (USA). *Blood* Dec 2016, 128 (22): 1242

Baron F, **Efficace F**, Cannella L, Mandelli F, Willemze R, Muus P, Marie J, Ferrero D, Dictus M, Fazi P, La Sala E, Bourhis J, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Bron D, Petti M, Halkes C, van der Velden W, Boccadoro M, Amadori S, Zittoun R, Suci S. Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study. 58th ASH Annual Meeting, San Diego, CA (USA). *Blood* Dec 2016, 128 (22): 2288

Efficace F, Gaidano G, Breccia M, Niscola P, Cottone F, Fianchi L, Voso MT, Caocci G, Buccisano F, Angelucci E, Santini V, Stauder R, Platzbecker U, Ricco A, Di Renzo N, Bowen D, Mandelli F. Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. *57th Annual Meeting of the American Society of Hematology (ASH)*, Orlando (FL). *Blood* (ASH Annual Meeting Abstracts), 126: (abs. 2099). 2015.

Efficace F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Pierri I, Nobile F, Rodeghiero F, Scaramucci L, Rambaldi A, Cascavilla N, Fabio F, Petrungraro A, Ditunno P, La Nasa G, Cirrincione S, Mandelli F,

Mazzucconi MG. Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic pITP Patients, *57th Annual Meeting of the American Society of Hematology (ASH)*, Orlando (FL). *Blood (ASH Annual Meeting Abstracts)*, 126: (abs. 2122). 2015.

Mercieca-Bebber RL, Perreca A, Macann A, King MT, Whale K, Soldati S, Jacobs M, **Efficace F**. Patient-Reported Outcomes in Randomised Controlled Trials of Head and Neck Cancers: A Systematic Review of Reporting Quality from the PROMOTION Registry. *22nd Annual Conference of the International Society for Quality of Life Research (ISOQOL)*, Vancouver, Canada. *Quality of Life Research* 24(1):114 (abs. 2007), 2015.

Cottone F, Giesinger JM, **Efficace F**. The impact of comorbidity on quality of life in elderly patients with chronic myeloid leukemia. *22nd Annual Conference of the International Society for Quality of Life Research (ISOQOL)*, Vancouver, Canada. *Quality of Life Research*, 24(1):129 (abs. 2081), 2015.

Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen KT, Platzbecker Y, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo G, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, **Efficace F**. Accuracy of physician assessment of treatment preferences and health status in patients with higher-risk myelodysplastic syndromes. *20th Congress of the European Hematology Association (EHA)*, Wien. *Haematologica* 2015; 100(s1):23. (abs. S147).

Malak S, Oerlemans S, **Efficace F**, Bredart A, Kyriakou C, Daniëls L, Creutzberg C, Cocks K, Sztankay M, Pallua S, Caocci G, Molica S, Chie W, van de Poll-Franse L Cross-Cultural development of four EORTC Questionnaires to assess quality of life in patients with Hodgkin, non-Hodgkin lymphoma and chronic lymphocytic leukemia. *20th Congress of the European Hematology Association (EHA)*, Wien, *Haematologica* 2015; 100(s1):149. (abs. P422).

Cartoni C, Tendas A, **Efficace F**, Niscola P, Soldati S, Brunetti GA, Meloni E, Minotti C, Cupelli L, Marini MG, Reale L, Martone N, Foà R, Alimena G, de Fabritiis P, Mandelli F. Hospital versus home care for patients with hematological malignancies in curative or terminal phase: use of the resources analysis, symptom burden and cost-effectiveness study. *20th Congress of the European Hematology Association (EHA)*, Vienna Jun 12, 2015; *Haematologica* 2015; 100(s1):24. (abs. S149).

Martins Y, Klaassen R, **Efficace F**, Buckstein R, Tinsley, Watts C, Jurcic J, Abel GA. Measuring quality of life in chronic hematologic malignancy: The QUALMS-1. ASCO Quality Care Symposium, Boston (MA), USA, October, 2014. *Journal of Clinical Oncology*, 32, (suppl 30; abstr 263), 2014.

Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F. A Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide versus Retinoic Acid and Chemotherapy in Acute Promyelocytic Leukemia Patients: Health-Related Quality of Life Outcomes. *20th Congress of the European Hematology Association (EHA)*, Wien. *Haematologica* 2014, 99(s1):516. (abs. S1330)

Dirven L, Taphoorn MJ, Reijneveld JC, Blazeby JM, Jacobs M, Pusic A, La Sala E, Fayers P, **Efficace F**. On behalf of EORTC Quality of Life Group (Patient Reported Outcome Measurements Over Time In ONcology-PROMOTION Registry). The level of patient-reported outcome reporting in randomized controlled trials of brain tumour patients. *21st Annual Conference of the International Society for Quality of Life Research (ISOQOL)*, Berlin, Germany. *Quality of Life Research*, 23(1):75 (abs.1049), 2014.

Rees J, Whale K, Fish D, Fayers P, Cafaro V, Pusic A, Blazeby JM, **Efficace F**. EORTC Quality of Life Group PROMOTION Registry. Patient-Reported Outcomes In Randomized Controlled Trials of Colorectal Cancers. Methodological Quality and Impact on Clinical-Decision-Making. *21st Annual Conference of the International Society for Quality of Life Research (ISOQOL)*, Berlin (Germany). *Quality of Life Research*, 23(1):54-55 (abs.210.4), 2014.

Efficace F, Cemal Y, Pusic A, Fayers P, Piciocchi A, Rees J, Blazeby JM. EORTC Quality of Life Group PROMOTION Registry. Methodological Quality of Patient-Reported Outcomes (PROs) In Breast Cancer Trials According to the CONSORT PRO Extension: Evidence from 123 Trials enrolling over 83,000 patients. *21st Annual Conference of the International Society for Quality of Life Research (ISOQOL)*, Berlin (Germany). *Quality of Life Research*, 23(1):55 (abs.210.5), 2014

Geissler J, **Efficace F**, Bombaci F, De Jong J, Gavin AM, et al. Factors Predicting Intentional Non-Adherence In Chronic Myeloid Leukemia: A Multivariate Analysis On 2546 Patients By The CML Advocates Network. 55th Annual Meeting of the *American Society of Hematology* (ASH), New Orleans (LA). *Blood* (ASH Annual Meeting Abstracts), 122: (abs. 4023). 2013.

Bredart A, Brito T, Arraras J, **Efficace F**, Kop J, Dolbeault S. Assessment of cancer outpatient satisfaction with care: a systematic review of self-reported instruments. (November, 2013). 15th *World Congress of Psycho-Oncology and Psychosocial Academy*.

Efficace F, Rambaldi A, Di Bona E, Fabbiano F, Cottone F, Breccia M, Avvisati G, Foà R, Morselli M, Bosi A, Caramatti C, Leoni P, Falini B, Romani C, Di Raimondo F, Mancini V, D'Ardia S, Martinelli G, Cassibba V, Finizio O, Cascavilla N, Carella AM, Vignetti M, Mandelli F, Lo Coco F. Long-Term Health Related Quality of Life and Symptom Burden in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid (ATRA) and Chemotherapy. 55th Annual Meeting of the *American Society of Hematology* (ASH), New Orleans (LA). *Blood* (ASH Annual Meeting Abstracts), 122: (abs. 770). 2013.

Efficace F, Santini V, La Nasa G³, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AN, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Vallisa D, Storti S, Voso MT, Alimena G, Fenu S, Vignetti M, Mandelli F, Angelucci E. Health-Related Quality of Life in Transfusion-Dependent Patients with Myelodysplastic Syndromes Treated with Deferasirox. A Multicenter Prospective Study. 55th Annual Meeting of the *American Society of Hematology* (ASH), New Orleans (LA). *Blood* (ASH Annual Meeting Abstracts), 122: (abs. 2980). 2013.

Van Leeuwen M, **Efficace F**, Fossa S, Bolla M, Holzner B, De Wit R, Van Poppel H, Osanto D, Aaronson NK. Methods and measures for assessing the HRQOL of long-term survivors of testicular and prostate cancer previously participating in EORTC phase II clinical trials. (October, 2013). 20th *Annual Conference of the International Society for Quality of Life Research*, Miami (FL), USA. *Quality of Life Research*, 22(1):135 (abs.3084), 2013.

Efficace F, Feuerstein M, Pusic A, Cafaro V, Fayers P, Blazeby J. (October, 2013). Patient-Reported Outcomes In Randomized Controlled Trials of Genitourinary Cancers. Methodological Quality and Impact on Clinical-Decision-Making. 20th *Annual Conference of the International Society for Quality of Life Research*, Miami (FL), USA. *Quality of Life Research*, 22(1):13 (abs.103.1), 2013.

Cottone F, **Efficace F**, Collins GS. (October, 2013). Propensity score matching and age-gender adjustment methods for quality of life comparisons between non-randomized groups: the influence of sample size on bias reduction. 20th *Annual Conference of the International Society for Quality of Life Research*, Miami (FL), USA. *Quality of Life Research*, 22(1):62 (abs.1027), 2013.

Cottone F, **Efficace F**, Rosti G, Breccia M, Castagnetti F, Iurlo A, Mandelli F, Baccarani M. (October, 2013). Profiling Chronic Myeloid Leukemia Patients Reporting Intentional and Unintentional Non-adherence to Lifelong Therapy with Tyrosine Kinase Inhibitors. 20th *Annual Conference of the International Society for Quality of Life Research*, Miami (FL), USA. *Quality of Life Research*, 22(1):23 (abs.204.1), 2013.

Rees J, Blazeby J, Pusic A, Feuerstein M, Whale K, Jacobs M, Kieffer J, Cemal Y, Fish D, Yanagawa J, Fayers P, **Efficace F**. (October, 2013). Concordance of patient reported (PROs) and clinical outcomes in randomized controlled trials (RCTs) of cancer treatment. Evidence from 192 RCTs of patients with solid tumors. 20th *Annual Conference of the International Society for Quality of Life Research*, Miami (FL), USA. *Quality of Life Research*, 22(1):13 (abs.103.2), 2013.

Efficace F, Cottone F, Vignetti M, Mandelli F, Angelucci E. (October, 2013). Quality of Life (QoL) and symptoms in transfusion-dependent patients with myelodysplastic syndromes (MDS) undergoing oral chelation therapy. 20th *Annual Conference of the International Society for Quality of Life Research*, Miami (FL), USA. *Quality of Life Research*, 22(1):137 (abs.3092), 2013.

Efficace F, Rosti G, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Naeem A, Cottone F, Oerlemans S, Castagnetti F, Bombaci F, Sharf G, Noens L, Pallua S, Mandelli F, Baccarani M. (June, 2013). Cross-cultural development of an EORTC Questionnaire for Assessing Quality of Life in Chronic Myeloid Leukemia Patients: The EORTC QLQ-CML24. 18th Congress of the *European Hematology Association (EHA)*, Stockholm, Sweden. *Haematologica* 98 (S1), 444 (abs. P1082).

Efficace F, Fazi P, Gaidano G, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Rodeghiero F, Pierri I, Nobile F, Rambaldi A, Cascavilla N, Scaramucci L, Forghieri F, Ditunno P, Caocci G, Petrungero A, Cirrincione S, Mercanti C, Soldati S,

Mandelli F, Mazzucconi MG. (June, 2013). Patterns of Fatigue in Patients with Primary Immune Thrombocytopenia: A Multicenter Observational Study. 18th Congress of the *European Hematology Association (EHA)*, Stockholm, Sweden. *Haematologica* 98 (S1), 445 (abs. P1085).

Sharf G, Hoffmann V, Bombaci F, Daban M, De Jong J, Gavin T, Pelouchova J, Dziwinski E, Eliasson L, **Efficace F**, Guillhot J, Geissler J. (June, 2013). Non-adherence in Chronic Myeloid Leukemia: Results of a global survey of 2546 CML patients in 79 countries. 18th Congress of the *European Hematology Association (EHA)*, Stockholm, Sweden. *Haematologica* 98 (S1), 453 (abs. S1104).

Caocci G, **Efficace F**, Cottone F, Vacca A, Piras E, Sanna M, Spanu G, Littera R, Lucarelli G, La Nasa G. (June, 2013). Quality of life and return to normal living patterns twenty years after transplantation for thalassemia. 18th Congress of the *European Hematology Association (EHA)*, Stockholm, Sweden. *Haematologica* 98 (S1), 444 (abs. P1083).

Efficace F, Rosti G, Cottone F, Vignetti M, Mandelli F, Baccarani M. (June, 2013). How accurate Are Physicians in Estimating Symptom Severity and Health Status of Their Chronic Myeloid Leukemia Patients? 18th Congress of the *European Hematology Association (EHA)*, Stockholm, Sweden,. *Haematologica* 98 (S1), 445 (abs. P1084).

Efficace F, Gaidano G, Breccia M, Voso MT, Caocci G, Stauder R, Angelucci E, Selleslag D, Sanpaolo MG, Platzbecker U, Jonasova A, Rauzy B, Buccisano F, Ricco A, Palumbo G, Bowen D, Nguyen K, Niscola P, Huiyong Z, Wan C, Lubbert M, Fenu S, Molica S, Balduini C, Focan C, Ciceri F, Di Renzo N, Chie W, Ackroyd S, Lunghi M, Klimek V, Cottone F, Vignetti M, Mandelli F. (June, 2013). Profiling patients with high-risk myelodysplastic syndromes who prefer to receive survival prognostic information. Final results from a large international prospective cohort observational study. 18th Congress of the *European Hematology Association (EHA)*, Stockholm, Sweden. *Haematologica* 98 (S1), 443 (abs. P1081).

Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F. (December, 2012). Tyrosine-Kinase Inhibitors, Quality of Life and Symptom Burden in Chronic Myeloid Leukemia: What Have we Learned So Far?. 54th Annual Meeting of the *American Society of Hematology (ASH)*, Atlanta (GA), USA. *Blood (ASH Annual Meeting Abstracts)*: 120: (abs. 4236). 2012.

Efficace F, Fazi P, Rodeghiero F, Gaidano G, Schinco P, Carpenedo M, Rambaldi A, Simula MP, De Fabritiis P, Ditunno P, Caocci G, Soldati S, Borchiellini A, Baldacci E, Daragjati J, Mandelli F, Mazzucconi M. (December, 2012). Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population. 54th Annual Meeting of the *American Society of Hematology (ASH)*, Atlanta (GA), USA. *Blood (ASH Annual Meeting Abstracts)*: 120: (abs. 2056). 2012.

Efficace F, Gaidano G, Voso MT, Caocci G, Breccia M, Stauder R, Selleslag D, Sanpaolo M, Platzbecker U, Criscuolo M, Di Tucci A, Lunghi M, Jonasova A, Buccisano F, Ricco A, Huiyoung Z, Bowen D, Palumbo G, Niscola P, Cottone F, Vignetti M, Mandelli F. (December, 2012). Patient-reported fatigue, functional aspects and quality of life in elderly patients with high-risk myelodysplastic syndromes. Evidence from a large prospective international study. 54th Annual Meeting of the *American Society of Hematology (ASH)*, Atlanta (GA), USA. *Blood (ASH Annual Meeting Abstracts)*: 120: (abs.3163). 2012.

Efficace F, Baccarani M, Breccia M, Cottone F, Rosti G, Alimena G, Lambertenghi Delilieri G, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti, Bergamaschi M, Scortechini A, Simula M, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F. (December, 2012). Fatigue Is The Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving long-term Imatinib therapy. 54th Annual Meeting of the *American Society of Hematology (ASH)*, Atlanta (GA), USA. *Blood (ASH Annual Meeting Abstracts)*: 120: (abs.4234). 2012.

Caocci G, **Efficace F**, Vacca A, Piras E, Sanna M, Spanu G, Littera R, Lucarelli G, La Nasa G. Quality of life in thalassemia patients twenty years after transplantation: long term outcome and return to normal life. 39th Annual Meeting of the *European Group for Blood and Marrow Transplantation (EBMT)* 7-10 Apr, 2013. London, UK. *Bone Marrow Transplantation* 2013; 48(S2),S57 (O370)

Cottone F, Collins GS, **Efficace F**. (October, 2012). Beyond age and gender adjustment when using reference data on Quality of Life: a propensity score matching approach. 19th Annual Conference of the *International Society for Quality of Life Research*, Budapest (Hungary). *Quality of Life Research*, 21:21 (abs.203.4). 2012

Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, Chie W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti

M, Baccarani M, Mandelli F, Sprangers M. (October, 2012). Cross-cultural development of an EORTC measure to assess quality of life (QoL) in patients with chronic myeloid leukemia (CML). 19th Annual Conference of the International Society for Quality of Life Research, Budapest (Hungary). *Quality of Life Research*, 21:24 (abs.205.4). 2012.

Efficace F, Gaidano F, Stauder R, Caocci G, Voso MT, Bowen D, Selleslag D, Di Tucci A, Lunghi M, Breccia M, Buccisano F, Platzbecker U, Cottone F, Vignetti M, Mandelli F. (October, 2012). Quality of Life and symptoms in patients with myelodysplastic syndromes (MDS). Investigating the role of transfusion dependency in an International study. 19th Annual Conference of the International Society for Quality of Life Research, Budapest (Hungary). *Quality of Life Research*, 21:8 (abs.104.4). 2012.

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Castagnetti F, Lambertenghi Delilieri G, Russo Rossi A, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F. (December, 2011). Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. 53rd Annual Meeting of the *American Society of Hematology* (ASH), San Diego (CA), USA. *Blood* (ASH Annual Meeting Abstracts) 118: (abs:1026).

Efficace F, Gaidano G, Stauder R, Caocci G, Voso MT, Criscuolo M, Selleslag D, Di Tucci AA, Lunghi M, Breccia M, Buccisano F, Platzbecker U, Cottone F, Vignetti M, Mandelli F. (December, 2011). Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. 53rd Annual Meeting of the *American Society of Hematology* (ASH), San Diego (CA), USA. *Blood* (ASH Annual Meeting Abstracts): 118: (abs:2078).

Efficace F, Breccia M, Saussele S, Kossak U, Caocci G, Sprangers M, Chie W, Naeem A, Nicolatou-Galitis O, Vignetti M, Cardoni A, Mandelli F, Baccarani M (December, 2011). International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML) 53rd Annual Meeting of the *American Society of Hematology* (ASH), San Diego (CA), USA. *Blood* (ASH Annual Meeting Abstracts): 118: (abs:3132).

Efficace F, Baccarani M, Breccia M, Alimena G, Cottone F, Rosti G, Lambertenghi Delilieri G, Baratè C, Russo Rossi A, Fioritoni G, Luciano L, Turri D, Nobile F, Di Raimondo F, Cuneo A, Bergamaschi M, Leoni P, Simula M, Levato L, Saglio G, Pizzolo G, Leone G, Rambaldi A, Pardini S, Gherlinzoni F, Zaccaria A, Tiribelli M, Vignetti M, Mandelli F (June, 2011). Socio-demographic and clinical determinants of patient-reported symptom severity in chronic myeloid leukemia survivors in treatment with Imatinib over the long run. 16th Congress of the *European Hematology Association (EHA)*, London, UK. *Haematologica* 96 (S2), 287 (abs. 0682)

Trawinska M, Niscola P, Tendas A, Giovannini M, Cupelli L, Palombi M, Brunetti G, Perrotti A, Cartoni C, **Efficace F**, de Fabritiis P, Mandelli F (June, 2011). Home care management of transfusions in hematological patients. 16th Congress of the *European Hematology Association (EHA)*, London, UK. *Haematologica* 96 (S2), 643 (abs. 1643)

Tendas A, Niscola P, Cupelli L, Dentamaro D, **Efficace F**, De Fabritiis P, Arcese W. Prospective evaluation of oral mucositis day by day assessment in hematological patients undergoing stem cell transplantation. 16th Congress of the *European Hematology Association (EHA)*, London, UK. *Haematologica* 96 (S2), 674 (abs. 1742). 2011.

Niscola P, Tendas A, Trawinska M, Giovannini M, Cupelli L, Palombi M, Brunetti G, Perrotti A, Cartoni C, **Efficace F**, de Fabritiis P, Mandelli F (June, 2011). Transfusions in home care patients with myelodysplastic syndromes. 16th Congress of the *European Hematology Association (EHA)*, London, UK. *Haematologica* 96 (S2), 518 (abs. 1267)

Efficace F, Gaidano G, Breccia M, Caocci G, Voso MT, Sprangers M, Criscuolo M, Lunghi M, Di Tucci A, Beyne-Rauzy O, Buccisano F, Deschler B, Platzbecker U, Cottone F, Vignetti M, Mandelli F. Desire for prognostic information and quality of life outcomes in patients with high-risk myelodysplastic syndromes. 18th Annual Conference of the International Society for Quality of Life Research, Denver, (CO). Proceedings of the ISOQOL Meeting, p.45 (abs.1015/405). 2011.

Cottone F, Baccarani M, Breccia M, Alimena G, Rosti G, Castagnetti F, Vignetti M, Mandelli F, **Efficace F**. (October, 2011). Patient-Reported Outcomes and Adherence to Long Term Therapy with Imatinib in Patients with Chronic Myeloid Leukemia. 18th Annual Conference of the International Society for Quality of Life Research, Denver, (CO). Proceedings of the ISOQOL

Meeting, p.45 (abs.1014/366). 2011.

Efficace F, Breccia M, Saussele S, Kossak U, Caocci G, Sprangers M, Chie W, Naeem A, Nicolatou-Galitis O, Vignetti M, Cardoni A, Mandelli F, Baccarani M. (October, 2011). *EORTC Quality of Life Group* Cross-cultural development of an EORTC questionnaire module to assess quality of life (QoL) in patients with chronic myeloid leukemia (CML). *18th Annual Conference of the International Society for Quality of Life Research*, Denver, (CO). Proceedings of the ISOQOL Meeting, p.19 (abs.307). 2011.

Cottone F, **Efficace F**, Ciotti F, Roncarolo MG, Vacca A, Piras E, Littera R, Suleiman R, Collins G, Ciceri F, Mandelli F, La Nasa G. (October, 2011). Parent-Child Perceptions of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia. *18th Annual Conference of the International Society for Quality of Life Research*, Denver, (CO). Proceedings of the ISOQOL Meeting, p.25 (abs.145). 2011.

F.Efficace (May, 2011). The added value of quality-of-life and other patient-reported outcomes in clinical research of patients with Myelodysplastic Syndromes. *11th International Symposium on Myelodysplastic Syndromes*. Edinburgh, (Scotland). *Leukemia Research* 35 (S1), S54 (abs.9), 2011.

F. Efficace, G. Alimena, MT. Voso, G. Caocci, A. Di Tucci, R. Stauder, G. Sanpaolo, G. Gaidano, M. Breccia, D. Selleslag, O. Beyne-Rauzy, S. Wood, F. Ciceri, G. Specchia, D. Bowen, F. Buccisano B. Deschler, R. Neuwirtova, C. Focan, S. Ackroyd, M. Criscuolo, R. Invernizzi, C. Ravoet, R. Paolini, G. Matta, S. Fenu, R. De Bock, E. Morra, F. Cottone, M. Vignetti, F. Mandelli. (May, 2011). Involvement in treatment decisions, desire for prognostic information and quality of life in high-risk myelodysplastic syndromes: the physician's perspective. *11th International Symposium on Myelodysplastic Syndromes*. Edinburgh, (Scotland). *Leukemia Research* 35 (S1), S57 (abs.147), 2011.

Caocci G, Pisano V, Vacca A, Piras E, Ledda A, Pizzati A, Littera R, **Efficace F**, La Nasa G. Health-related quality of life assessment during high-dose chemotherapy and stem cell transplantation in patients with haematologic malignancies. *37th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT)*. Paris, France. *Bone Marrow Transplantation* 46 (S1), S172 (abs. 0660), 2011

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Lambertenghi Delilieri G, Baratè C, Russo Rossi A, Fioritoni G, Luciano L, Turri D, Nobile F, Di Raimondo F, Cuneo A, Gobbi M, Leoni P, Simula M, Levato L, Saglio G, Pizzolo G, Leone G, Rambaldi A, Pardini S, Gherlinzoni F, Zaccaria A, Tiribelli M, Cottone F, Vignetti M, Mandelli F. (December, 2010). Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter study including 448 patients. *52nd Annual Meeting of the American Society of Hematology (ASH)*, Orlando, (FL), USA. *Blood (ASH Annual Meeting Abstracts)* 116: (abs.2273).

Efficace F, Breccia M, Baccarani M, Vignetti M, Mandelli F. (December, 2010). Health-Related Quality of life in Patients with Chronic Myeloid Leukemia: what have we learned over the last twenty years? *52nd Annual Meeting of the American Society of Hematology (ASH)*, Orlando, (FL), USA. *Blood (ASH Annual Meeting Abstracts)* 116: (abs.3423).

Efficace F, Gaidano G, Voso MT, Caocci G, Breccia M, Di Tucci A, Stauder R, Selleslag D, Wood S, Wan C, Sanpaolo G, Lunghi M, Balducci L, Cottone F, Vignetti M, Mandelli F. (December, 2010). Investigating preferences and factors associated with involvement in treatment decision making in newly diagnosed patients with high-risk myelodysplastic syndromes: an international multicenter study. *52nd Annual Meeting of the American Society of Hematology (ASH)*, Orlando, (FL), USA. *Blood (ASH Annual Meeting Abstracts)* 116: (abs.4953).

Caocci G, **Efficace F**, Ciotti F, Chiesa R, Roncarolo MG, Vacca A, Piras E, Raji M, Collins G, Mandelli F, Marktel S, La Nasa G. (October, 2010). Longitudinal assessment of health related quality of life via child and parent-proxy reports in children with thalassemia following hematopoietic stem cell transplantation. *17th Annual Conference of the International Society for Quality of Life Research*, London, UK. *Quality of Life Research*, 19 (Suppl 1):140, (abs.1313).

Vivat B, Young T, Arraras J, Ásgeirsdóttir G, Bredart A, Costantini A, **Efficace F**, Kobayashi K, Sigurdadóttir V, Singer S. (October, 2010). Developing and utilizing the EORTC QLQ-SWB33: a spiritual wellbeing measure for palliative care patients with cancer. *17th Annual Conference of the International Society for Quality of Life Research*, London, UK. *Quality of Life*

Research, 19 (Suppl 1):30, (abs.1246).

Efficace F, Breccia M, Bacarani M, Alimena G, Lambertenghi Delilieri G, Specchia G, Cottone F, Vignetti M, Mandelli F. (October, 2010). Symptom burden in chronic myeloid leukemia survivors treated with Imatinib. 17th Annual Conference of the International Society for Quality of Life Research, London, UK. *Quality of Life Research*, 19 (Suppl 1):27, (abs.1575).

Efficace F, Breccia M, Cocks M, Sprangers M, Vignetti M, Mandelli F. (October, 2010). Patient-reported outcomes in Chronic Myeloid Leukemia: what do we know? A systematic review from 1980 to 2010. 17th Annual Conference of the International Society for Quality of Life Research, London, UK. *Quality of Life Research*, 19 (Suppl 1):89, (abs.1559).

Efficace F, Gaidano G, Voso MT, Sprangers M, Breccia M, Caocci G, Angelucci E, Lunghi M, Criscuolo M, Di Tucci A, Cascavilla N, Specchia G, Capalbo S, Cottone F, Vignetti M, Mandelli F. (October, 2010). Factors affecting overall quality of life in untreated patients with hematological malignancies. 17th Annual Conference of the International Society for Quality of Life Research, London, UK. *Quality of Life Research*, 19 (Suppl 1):90, (abs.1526).

Efficace F, Angelucci E, Sprangers M, Gaidano G, Caocci G, Breccia M, Voso MT, Stauder R, Selleslag D, Lübbert M, Cascavilla N, Rauzy B, Chonghua W, Specchia G, Chie W, Focan C, Cottone F, Vignetti M, Mandelli F. (June, 2010). Investigating pretreatment quality of life and symptomatology in newly diagnosed high-risk patients with myelodysplasia. 15th Congress of the European Hematology Association (EHA), Barcelona, Spain. *Haematologica* 95 (S2), 187 (abs. 0460)

Efficace F, Bacarani M, Vignetti M, Fazi P, Breccia M, Alimena G, Lambertenghi Delilieri G, Specchia G, Meloni E, Mandelli F. (June, 2010). The Value of Patient Associations in hematology clinical research: challenges and preliminary results of a joint study investigating health outcomes in patients with chronic myeloid leukemia. 15th Congress of the European Hematology Association (EHA), Barcelona, Spain. *Haematologica* 95 (S2), 191 (abs. 0471)

Efficace F, Breccia M, Bacarani M, Alimena G, Lambertenghi Delilieri G, Specchia G, Cottone F, Vignetti M, Mandelli F. (June, 2010). Development and feasibility of a patient-reported symptom checklist for chronic myeloid leukemia patients. 15th Congress of the European Hematology Association (EHA), Barcelona, Spain. *Haematologica* 95 (S2), 189 (abs. 0465)

Cartoni C, **Efficace F**, Tendas A, Niscola P, Brunetti G, Marini MG, Reale L, Federico V, Minotti C, Finsinger P, Loglisci MG, Meloni E, Mandelli F. (June, 2010). Assessing symptoms in hematology from the patient's perspective: feasibility of a patient-reported instrument in clinical research. 15th Congress of the European Hematology Association (EHA), Barcelona, Spain. *Haematologica* 95 (S2), 188 (abs. 0463)

Caocci G, **Efficace F**, Ciotti F, Chiesa R, Roncarolo MG, Vacca A, Piras E, Raji M, Collins G, Mandelli F, Markt S, La Nasa G. (March 2010). Longitudinal assessment of health-related quality of life and healthcare satisfaction after hematopoietic stem cell transplantation in children with thalassemia. 36th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT). Wien, Austria. *Bone Marrow Transplantation* 45 (S2), 58 (abs. 0344).

Efficace F, Cartoni C, Niscola P, Marini MG, Reale L, Cottone F, Tendas A, Loglisci M, Federico V, Meloni E, De Fabritiis P, Mandelli F. (October, 2009). Patient-Reported symptom burden in supportive and palliative care in hematology. A feasibility study using the M.D. Anderson Symptom Inventory (MDASI). 16th Annual Conference of the International Society for Quality of Life Research, New Orleans, Louisiana, USA. *Quality of Life Research*, A-52, (abs.1588).

Giesinger J, Kemmler G, Oberguggenberger A, Incrocci L, Johnson C, Arraras J, **Efficace F**, Aaronson N, Chow E, Harris K, Lockett T, Holzner B. (October, 2009). Quality of life assessment in testicular cancer patients: EORTC module development and implementation in clinical practice. . 16th Annual Conference of the International Society for Quality of Life Research, New Orleans, Louisiana, USA. *Quality of Life Research*, A-77, (abs.1578).

Efficace F, Caocci G, Vignetti M, Fazi P, Cottone F, La Nasa G, Mandelli F. (October, 2009). Quality of life and symptom assessment in patients with myelodysplastic syndromes (MDS). An evaluation of the methodology and the quality of reported outcomes. 16th Annual Conference of the International Society for Quality of Life Research, New Orleans, Louisiana, USA. *Quality of Life Research*, A-52, (abs.1582).

Caocci G, **Efficace F**, Vignetti M, Mandelli F, Fazi P, Ledda A, La Nasa G (October, 2009). Health-related quality of life of

patients with myelodysplastic syndromes- a systematic review from 1980 to 2008. 42th Congress of the Italian Society of Hematology, Milan, Italy. *Haematologica* 94 (S4), 111 (abs.151).

Weis J, **Efficace F**, Conroy T, Holzner B, Hammerlid E, Griffin A, Lanceley A, Arraras J, Singer S, Fleissner C, Bottomley A, Wirtz M, Flechtner H, (June, 2009). Development of an EORTC quality of life fatigue module phase III. 11th World Congress of Psycho-Oncology, Wien, Austria. *Psycho-Oncology*, 18, Suppl. 2, IL 2.27.2, S87.

Efficace F, Caocci G, Vignetti M, Mandelli F, Fazi P, Cottone F, La Nasa G. (June, 2009). What has been learned from measuring patient-reported outcomes in clinical research of patients with myelodysplastic syndromes? A systematic review from 1980 to 2008. 14th Congress of the European Hematology Association (EHA), Berlin, Germany. *Haematologica* 94 (S2), 452 (abs. 1115).

Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. (June, 2008). Patient-reported outcomes in leukemia randomized controlled trials. A systematic review to evaluate the added value in supporting clinical decision-making. 13th Congress of the European Hematology Association (EHA), Copenhagen, Denmark. *Haematologica* 93 (S1), 354 (abs. 0893).

Cartoni C, Breccia M, **Efficace F**, D'Elia GM, Brunetti G, Morano SG, Finolezzi E, Ribersani M, Balducci E, Foà R, Mandelli F. (June, 2008). Symptoms evaluation in hematologic palliative care patients admitted to an hospital-based home care program. 13th Congress of the European Hematology Association (EHA), Copenhagen, Denmark. *Haematologica* 93 (S1), 322 (abs. 0809).

Pucciarelli S, Del Bianco P, Serpentine S, Toppan P, De Paoli A, Capirci C, **Efficace F**, Cuicchi D, Amato A, Nitti D. (June, 2008). Patient-reported outcomes following preoperative chemoradiotherapy for rectal cancer: a prospective multicenter observational study. 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL (USA). *Journal of Clinical Oncology supplement* 26 (15S), 202 (abs.4099).

Caocci G, Pisu S, **Efficace F**, Orofino MG, Argioli F, Vacca A, Piras E, Collins G, Littera R, Arras M, Ledda A, Pizzati A, La Nasa G. (April, 2008). Communication bias during the decision making process for unrelated bone marrow transplantation in adult thalassemia patients. 34th Annual Meeting of the European Group For Blood and Marrow Transplantation (EBMT). Florence, Italy. *Bone Marrow Transplantation* 41 (suppl. 1), S30, (abs. O185).

Molica S, Mauro F, Vignetti M, Foà R, **Efficace F**. (December, 2007). What have we learned from measuring health-related quality of life in patients with chronic lymphocytic leukemia? A systematic review of published studies from 1990 to 2007. 49th Annual Meeting of the American Society of Hematology (ASH), Atlanta, (Georgia), USA. *Blood* 110(11), (abs. 4718).

Weis J, Gao Y, Conroy T, Singer S, Hammerlid E, Holzner B, Fleissner C, **Efficace F**, Arraras J, Bottomley A, Flechtner H, Lanceley A, Jones L. (October, 2007). Development of an EORTC module for the assessment of cancer related fatigue (EORTC FAR 15): phase III results. 14th Annual Conference of the International Society for Quality of Life Research, Toronto (Canada). *Quality of Life Research*, A-108, (abs.1624).

Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F. (October, 2007). The independent prognostic value of quality of life parameters in advanced colorectal cancer. Results of an international validation study by the EORTC Chronotherapy Group. 14th Annual Conference of the International Society for Quality of Life Research, Toronto (Canada). *Quality of Life Research*, A-30, (abs.1263).

Efficace F, Vignetti M, Holzner B, Molica S, Kemmler G, Mandelli F. (October, 2007). What has been learned from measuring health-related quality of life in randomized controlled trials (RCTs) of leukemia patients? A systematic review from 1980 to 2007. 14th Annual Conference of the International Society for Quality of Life Research, Toronto (Canada). *Quality of Life Research*, A-72, (abs.1264).

Brédart A, Blazeby J, Conroy T, Chie W, Arraras J, Bergenmar M, **Efficace F**, Costantini A, Aaronson N, for the EORTC Quality of Life Group. (October, 2007). Assessment of patient satisfaction among oncology inpatients and outpatients by the EORTC Quality of Life Group. 14th Annual Conference of the International Society for Quality of Life Research, Toronto (Canada). *Quality of Life Research*, A-20, (abs.1219).

Toppan P, **Efficace F**, Del Bianco P, Serpentine S, De Salvo G, Nitti D, Pucciarelli S. (October, 2007). Investigating long term health-related quality of life outcomes in rectal cancer patients after curative surgery. *14th Annual Conference of the International Society for Quality of Life Research*, Toronto (Canada). *Quality of Life Research*, A-69, (abs.1276).

Tuveri M, Caocci G, Pisu S, Medas, F, **Efficace F**, Collins GS. (October, 2007). Investigating doctor-patient communication during the informed consent process in a cohort of patients undergoing surgery. *14th Annual Conference of the International Society for Quality of Life Research*, Toronto (Canada). *Quality of Life Research*, A-111, (abs.1672).

Efficace F, Bottomley A, Coens C. (October, 2006). Which is the most frequently used health-related quality of life (HRQOL) measure in cancer clinical trials? *8th World Congress of Psycho-Oncology*, Venice, (Italy). *Psycho-Oncology supplement 15(2)*, S135, (abs.319).

Arraras J, **Efficace F**, Holzner B, Vlastic K, Bjordal K. (October, 2006). Development of an EORTC questionnaire to assess information received by cancer patients: the EORTC QLQ-INFO26. Present results and future steps. *8th World Congress of Psycho-Oncology*, Venice, (Italy). *Psycho-Oncology supplement 15(2)*, S232, (abs.545).

Efficace F. Mind, body and time: circadian rhythms in psycho-oncology. (October, 2006). *8th World Congress of Psycho-Oncology*, Venice, (Italy). *Psycho-Oncology supplement 15(2)*, S58, (abs.135).

Young TE, Vivat B, **Efficace F**, Sigurðardóttir V. (October, 2006). International development of an EORTC Spiritual Wellbeing Module. *8th World Congress of Psycho-Oncology*, Venice, (Italy). *Psycho-Oncology supplement 15(2)*, S130, (abs.307).

Efficace F, Horneber M, Lejeune S, Van Dam F, Aaronson N. (October, 2006). Investigating the quality of patient-reported outcome research in complementary and alternative medicine interventions in oncology. *8th World Congress of Psycho-Oncology*, Venice, (Italy). *Psycho-Oncology supplement 15(2)*, S233, (abs.546).

Bottomley A, **Efficace F**, Gaafar R, Coens C, Manegold C, Burgers S, Vincent M, Giaccone G, Legrand C, Passioukov A, van Klaveren B, van Meerbeeck J. (October, 2006). Predicting survival using patient reported health status information from malignant pleural mesothelioma patients. *13th Annual Conference of the International Society for Quality of Life Research*, Lisbon (Portugal). *Quality of Life Research*, A-89, (abs.1423).

Mauer M, Taphoorn M, Bottomley A, **Efficace F**, Delattre J, Brandes A, van der Rijt CC, Bernsen HJJA, Frenay M, Tijssen CC, Coens C, Lacombe D, Allgeier A, van den Bent MJ. (October, 2006). An investigation into the value of symptom and health related quality of life data as prognostic factors in newly diagnosed anaplastic oligodendrogliomas patients. *13th Annual Conference of the International Society for Quality of Life Research*, Lisbon (Portugal). *Quality of Life Research*, A-111, (abs.1391).

Van Andel G, Bottomley A, Fossa S, **Efficace F**, Coens C, Aaronson N. (October, 2006). An International field study of psychometrics of the EORTC QLQ-PR25 questionnaire in assessing the health-related quality of life of patients with prostate cancer. *13th Annual Conference of the International Society for Quality of Life Research*, Lisbon (Portugal). *Quality of Life Research*, A-147, (abs.1587).

Efficace F (October, 2006). Investigating the value of patient's self-reported quality of life data in predicting survival in advanced cancer: Results of a large scale EORTC project. *13th Annual Conference of the International Society for Quality of Life Research*, Lisbon (Portugal). *Quality of Life Research*, A-11, (abs.1342).

Efficace F, Coens C, Bottomley A. (October, 2006). Is there a difference in the methodological quality of health-related quality of life assessment between academic and industry sponsored studies? Evidence from randomized controlled trials in oncology. *13th Annual Conference of the International Society for Quality of Life Research*, Lisbon (Portugal). *Quality of Life Research*, A-78, (abs.1304).

Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J, (October, 2006). Investigating model selection stability in predicting survival with health related quality of life data in advanced cancer patients. A multivariate analysis of prognostic factors of EORTC 08975. *13th Annual Conference of the International Society for Quality of Life Research*, Lisbon (Portugal). *Quality of Life Research*, A-

104, (abs.1300).

Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne CH. (October 2005). The prognostic value of health related quality of life in colorectal cancer patients: A multivariate analysis using a bootstrap model-averaging approach. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2137 (abs.1030).

Bottomley A, Smit E, **Efficace F**, Schramel F, Smit HJ, Gaafar R, Biesma B, Lianes P, Van Steen K, Coens C, Van Meerbeeck JP. (October 2005). Non-small cell lung cancer and health-related quality of life (HRQOL): is baseline HRQOL of prognostic value for survival? *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2050 (abs1013).

BottomleyA, **Efficace F**, Stupp R, Van Steen K, Coens C, Osoba D, Van den Bent M, Mason W, Cairncross G, Eisenhauer E, Wong R, Villa S, Mirimanoff R, Reni M, Taphoorn MJ. (October 2005). A bootstrap model averaging technique to investigate the prognostic value for survival of quality of life information. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2136 (abs.1022).

Brédart A, Bottomley A, Blazeby J, Conroy T, Coens C, D'Haese S, Chie W, Hammerlid E, **Efficace F**, Sezer O. (October 2005). An International Prospective Study of the EORTC Cancer In-Patient Satisfaction with Care Measure (EORTC IN-PATSAT32). *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2096 (abs.1053).

Flechtner H, Bottomley A, **Efficace F**, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E. (October 2005). Health Related Quality of Life Outcomes in EORTC Cancer Clinical Trials: What's been the impact? *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2052 (abs.1122).

Efficace F, Gotay C, Sprangers MA, Osoba D, Flechtner H, Biganzoli L, D'Haese S, Coens C, Bottomley A. (October, 2005). Exploring the *quality* of health-related quality of life (HRQOL) research in cancer clinical trials. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2002 (abs.1366).

Arraras J, **Efficace F**, Holzner B, Vlastic K, Bjordal K, Yun YH, Mills J, Greimel E, Velikova G, Visser A, Eisemann M. (October, 2005). Preliminary results of the design and development of an EORTC Information questionnaire: the EORTC QLQ-INFO 26. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2025 (abs.1516).

Brédart A, Coens C, Conroy T, **Efficace F**, Blazeby J, Chie W, Hammerlid E, Rodary C, Sezer O, Bottomley A. on behalf of the EORTC Quality of Life Group and Unit. (October, 2005). Factors related to patient satisfaction in oncology settings: Findings from an international study. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2037 (abs.1379).

Coens C, **Efficace F**, Bottomley A. (October, 2005). An evaluation of the sensitivity of different analysis techniques using HRQOL data. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2051 (abs.1270).

Coens C, Therasse P, **Efficace F**, Bottomley A. (October, 2005). Establishing baseline quality of life reference data for the EORTC QLQ-C30 in locally advanced breast cancer patients. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 1998 (abs.1261).

Young TE, Vivat B, **Efficace F**, Sigurðardóttir V. (October, 2005). International development of an EORTC Spiritual Wellbeing Module. *12th Annual Conference of the International Society for Quality of Life Research*, San Francisco, CA (USA). *Quality of Life Research* 14(9): 2104 (abs.1523).

Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Köhne CH, Schoffski P, Schmoll P, Van Cutsem E. On behalf of the EORTC Gastrointestinal Tract Cancer Group. (May, 2005). The value of patient-reported symptoms as prognostic factors for survival in advanced colorectal cancer. *41th Annual Meeting of the American Society of Clinical Oncology (ASCO)*,

Orlando, FL (USA). *Journal of Clinical Oncology supplement* 23 (16S): 267 (abs.3585).

Bottomley A, Taphoorn MJ, Coens C, Osoba D, van Steen K, **Efficace F**, van den Bent M, Mason W, Eisenhauer E, Stupp R. (May, 2005). Predicting survival using health-related quality of life scores in glioblastoma cancer: findings from an international phase III randomized controlled trial. *41th Annual Meeting of the American Society of Clinical Oncology (ASCO)*, Orlando, FL (USA). *Journal of Clinical Oncology supplement* 23 (16S): 861 (abs.9601).

Efficace F, Bottomley A, Osoba D, Gotay C, Sprangers MA, Flechtner H, Coens C, D'Haese S, Biganzoli L. (October 2004). Has the *quality* of health-related quality of life (HRQOL) reporting in cancer research improved over time? *29th Congress of European Society for Medical Oncology (ESMO)*, Wien (Austria). *Annals of Oncology supplement* 15(3): 123 (abs.460).

Bottomley A, Therasse P, **Efficace F**, Coens C, Gotay C, Welnicka-Jaskiewicz M, Cufer T, Dyczka J, Lichinitser M, Piccart M. (October, 2004). Long term health-related quality of life (HRQOL) in locally advanced breast cancer (LABC) survivors: results from a EORTC-NCIC-SAKK randomized controlled trial. *29th Congress of European Society for Medical Oncology (ESMO)*, Wien (Austria). *Annals of Oncology supplement* 15(3): 34 (abs.127)

Efficace F, Therasse P, Piccart M, Coens C, Van Steen K, Welnicka-Jaskiewicz M, Cufer T, Lichinitser M, Shepherd L, Bottomley A. (June, 2004). Predicting survival with health-related quality of life scores in locally advanced breast cancer: results from an international randomized controlled trial. *40th Annual Meeting of the American Society of Clinical Oncology (ASCO)*, New Orleans, LA, (USA). *Journal of Clinical Oncology supplement* 22 (14S): 31 (abs.618).

Efficace F, Bottomley A, Osoba D, D'haese S, Zurlo A. (May 2003). The impact of health-related quality of life (HRQOL) assessment in prostate cancer research. Does it provide meaningful support for decision-making policy? *39th Annual Meeting of the American Society of Clinical Oncology (ASCO)*, Chicago, IL, (USA). *Proceedings of the American Society of Clinical Oncology* 22:426 (abs.1713).

Vivat B, Young T, de Graeff A, **Efficace F**, Holzner B, Sigurdardottir V, van den Eynden B, Visser A, Vlastic K. (April, 2003). Early stages of development of EORTC modules on Social Support and Spiritual Wellbeing. *Proceedings of the 8th Congress of the European Association for Palliative Care*, The Hague, The Netherlands.

Efficace F. (June, 2003). The value of self-rating questionnaires in research of mental healthcare in oncology. *International Thematic Conference Diagnosis in Psychiatry: Integrating the Sciences (World Psychiatry Association)*. Wien, (Austria). *World Psychiatry* 2 (Suppl.1):50 (abs.S43.2).

Efficace F, Bottomley A, Blazeby JM. (September 2003). Health-related quality of life in randomized controlled trials in colorectal cancer. *ECCO 12 –The European Cancer Conference, Copenhagen, Denmark. European Journal of Cancer Supplements*, 1(5), (S271). (abs.904).

Efficace F, Bottomley A, Vanvoorden V, Velikova G, Greimel E, Van Andel G. (September 2003). The level of reporting of health-related quality of life in cancer research. Evidence from 123 randomised controlled trials enrolling 36220 cancer patients. *ECCO 12 –The European Cancer Conference, Copenhagen, Denmark. European Journal of Cancer Supplements*, 1(5), (S274). (abs.910).

Bottomley A, **Efficace F**, Thomas R, Vanvoorden V, Ahmedzai S (September 2003). Health related quality of life (HRQOL) in randomised controlled trials for non small-cell lung (NSCLC) cancer patients – what is the added clinical value. *ECCO 12 – The European Cancer Conference, Copenhagen, Denmark. European Journal of Cancer Supplements*, 1(5), (S23), (abs.59).

Bottomley A, **Efficace F**, Vanvoorden V, Velikova G, Greimel E, Van Andel G. (November, 2003). What is the added clinical value of health related quality of life (HRQOL) studies in randomized controlled trials (RCTs)? Results from more than 100 trials. *10th Annual Conference of the International Society for Quality of Life Research*, Prague, Czech Republic. *Quality of Life Research* 12(7):766 (abs.1234).

Efficace F, Bottomley A, Blazeby JM, Vanvoorden V. (November, 2003). The impact on clinical decision-making of randomized controlled trials including health-related quality of life in colorectal cancer. *10th Annual Conference of the*

International Society for Quality of Life Research, Prague, Czech Republic. Quality of Life Research 12(7):767 (abs.1384).

Efficace F, Bottomley A, (June, 2002). Quality of life measurement issues in breast cancer clinical trials. *14th International Symposium of Supportive Care in Cancer*, Boston, MA, (USA). *Supportive Care in Cancer 10(4): 356.*

Efficace F, Bottomley A, (June, 2002). Quality of life assessment in randomized controlled trials with primary brain tumor patients. *14th International Symposium of Supportive Care in Cancer*, Boston, MA, (USA). *Supportive Care in Cancer 10(4): 356.*

Efficace F, Bottomley A, van Andel G, (November, 2002). Quality of life assessment in randomized controlled trials with prostate cancer patients. An evaluation of the methodology and the quality of reported outcomes. *9th Annual Conference of the International Society for Quality of Life Research*, Orlando, FL, (USA). *Quality of Life Research 11(7): 624 (abs.13).*

Efficace F, Fioravanti D. Buckley A. E. (April, 2002). Issues and prospectives for quality of life assessment in psychogeriatrics. *Proceedings of the European and Mediterranean Regional Meeting of the International Psychogeriatric Association*, Rome, (Italy).

Bottomley A, **Efficace F**, (November, 2002). The methodological quality of Health Related Quality of Life (HRQOL) in randomized controlled trials in non-small cell lung cancer patients (NSCLC). *9th Annual Conference of the International Society for Quality of Life Research*, Orlando, FL, (USA). *Quality of Life Research 11(7): 667 (abs.182).*

Efficace F, Bottomley A, (November, 2002). The impact and outcome of quality of life assessment in randomized controlled trials in primary brain tumor patients. *9th Annual Conference of the International Society for Quality of Life Research*, Orlando, FL, (USA). *Quality of Life Research 11(7): 677 (abs.224).*